stockrow
Friday 6 November 2026
Export AXSM’s income statement to Excel — free account
Axsome Therapeutics, Inc.
AXSM Healthcare Biotechnology
Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +73.9%
- Free cash flow
- −1,078.3%
- Total debt
- +4.04%
Quarter to September 2026, against a year earlier
132.13
2.33
+1.80%
Follow AXSM
Alert me
Axsome Therapeutics, Inc. (AXSM) Revenue growth
Axsome Therapeutics, Inc.'s revenue growth over the twelve months to 30 September 2026 was 54.2%, down 11.4 percentage points from fiscal 2025 (65.6%). That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 65.6% | 23.02 |
| FY2024 | 42.5% | (398.27) |
| FY2023 | 440.8% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 51.9% | 6.33 |
| Jun 2026 | 45.5% | (11.88) |
| Mar 2026 | 57.4% | (7.61) |
| Dec 2025 | 65.0% | 1.81 |
| 10 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| PRAX Praxis Precision Medicines, Inc. compare | 249.5% |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 61.0% |
| AXSM Axsome Therapeutics, Inc. | 54.2% |
| MIRM Mirum Pharmaceuticals, Inc. compare | 42.2% |
| LGND Ligand Pharmaceuticals Incorporated compare | 1.03% |
| IONS Ionis Pharmaceuticals, Inc. compare | −7.41% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| ABVX Abivax SA Sponsored ADR compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on AXSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement